U.S. market Closed. Opens in 10 hours 4 minutes

TNGX | Tango Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 3.73 - 4.03
52 Week Range 2.7000 - 13.01
Beta 0.99
Implied Volatility 290.07%
IV Rank 61.73%
Day's Volume 1,186,030
Average Volume 1,885,626
Shares Outstanding 107,418,000
Market Cap 417,856,020
Sector Healthcare
Industry Biotechnology
IPO Date 2020-09-03
Valuation
Profitability
Growth
Health
P/E Ratio -3.38
Forward P/E Ratio N/A
EPS -1.15
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 140
Country USA
Website TNGX
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
*Chart delayed
Analyzing fundamentals for TNGX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see TNGX Fundamentals page.

Watching at TNGX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on TNGX Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙